Academic Journal
Q1Journal of the Peripheral Nervous System
About Journal of the Peripheral Nervous System
Journal of the Peripheral Nervous System is a scholarly journal published by Wiley-Blackwell Publishing Ltd. SCImago 2025 lists it in Q1, with an SJR of 0.941 and H-index of 82.
Coverage: 1996-2026. Research categories: Medicine (miscellaneous) (Q1); Neurology (clinical) (Q2); Neuroscience (miscellaneous) (Q2).
Verified field sources
- Editor(s): Giuseppe Lauria, M.D. (Editor) — Official source; checked 2026-10-03. Editorial leadership listed under Edited By on the Wiley journal homepage; publisher role retained without assuming Editor-in-Chief.
- Journal Impact Factor: 3.0 — Official source; checked 2026-10-03. Journal Impact Factor and reporting year from Wiley Journal Metrics, distinct from CiteScore and Journal Citation Indicator.
- Impact Factor year: 2025 — Official source; checked 2026-10-03. Journal Impact Factor and reporting year from Wiley Journal Metrics, distinct from CiteScore and Journal Citation Indicator.
Source-backed journal facts
Topics in published research
Hereditary Neurological Disorders; Peripheral Neuropathies and Disorders; Pain Mechanisms and Treatments; Botulinum Toxin and Related Neurological Disorders; Nerve injury and regeneration; Peripheral Nerve Disorders.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Reported open-access list prices
4,550.00 USD; 3,750.00 EUR; 3,070.00 GBP
APC list prices reported by OpenAlex, which obtains this information from DOAJ. Confirm current charges, taxes, waivers and eligibility with the publisher; this is not a fee quotation.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Rituximab With or Without Chemotherapy for Anti‐ MAG Neuropathy: A Retrospective Multicenter Real‐World Study
Delmont Emilien, Cintas Pascal, Tard Céline, Boucraut José et al.
2026-12 · DOI: 10.1111/jns.70175Response to “Guillain‐Barré Syndrome in Chile: The Impact of Case Definitions on Incidence Estimates”
Gonzalo Rivera‐Lillo, Rayén Galiá‐Llaña, Matías Otto‐Yáñez, Rodrigo Torres‐Castro et al.
2026-12 · DOI: 10.1111/jns.70171Guillain–Barré Syndrome in Chile: The Impact of Case Definitions on Incidence Estimates
Juan Francisco Idiáquez Rios, Rodrigo Salinas, Gabriel Cea
2026-12 · DOI: 10.1111/jns.70161Cardiovascular Autonomic Neuropathy in Charcot–Marie–Tooth Disease: A Genotype‐Stratified Study of PMP22 Duplication and GJB1 Mutation Carriers
Kryštof Prášil, Veronika Potočková, Tomáš Nedělka, Alžběta Prášilová et al.
2026-12 · DOI: 10.1111/jns.70173Fampridine for Symptomatic Treatment in Chronic Inflammatory Demyelinating Polyneuropathy: A Randomized, Double‐Blinded, Placebo‐Controlled Crossover Study
Peter Nørregaard Hansen, Lars Markvardsen, Hatice Tankisi, Henning Andersen et al.
2026-12 · DOI: 10.1111/jns.70172Issue Information
2026-12 · DOI: 10.1111/jns.70129Newly Developing IgM Anti‐ GD1a / GD1b Ganglioside IgM Monoclonal Gammopathy in a Patient With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Ruby F. Ross, Jennifer A. Langsdorf, Norman Latov
2026-12 · DOI: 10.1111/jns.70174Complement‐Regulated Nodal Vulnerability in Guillain–Barré Syndrome and CIDP
Nobuhiro Yuki
2026-09 · DOI: 10.1111/jns.70165Reply to the Letter to the Editor “From Discrimination to Clinical Utility: Next Steps for the Erasmus Polyneuropathy Symptom Score”
Noor E. Taams, Merel Huijg, Pieter A. van Doorn
2026-09 · DOI: 10.1111/jns.70170Correction to “Epidemiology, Presentation, Management and Outcomes in Chronic Inflammatory Demyelinating Polyneuropathy in Birmingham, UK : The Impact of Ethnicity”
2026-09 · DOI: 10.1111/jns.70169From Discrimination to Clinical Utility: Next Steps for the Erasmus Polyneuropathy Symptom Score
Yasin Taşkın
2026-09 · DOI: 10.1111/jns.70168Abstract
2026-09 · DOI: 10.1111/jns.70152Issue Information
2026-09 · DOI: 10.1111/jns.70151High Resolution 3‐T Magnetic Resonance Tractography Cannot Localise Conduction Block in Multifocal Motor Neuropathy With Conduction Block
Ryan Y. S. Keh, Laura Zambreanu, Stephen Wastling, Carolynne M. Doherty et al.
2026-09 · DOI: 10.1111/jns.70164Impact of Baseline Polyneuropathy Severity on Eplontersen Efficacy in the NEURO ‐ TTRansform Clinical Trial
Thomas H. Brannagan, Markus Weiler, Márcia Waddington Cruz, Sami Khella et al.
2026-09 · DOI: 10.1111/jns.70167Hypoxia‐Induced Lactylation of NSUN3 Promotes m5C Methylation of SETD2 to Regulate Peripheral Nerve Injury Repair
Shuai An, Jingfei Shi, Jiang Huang, Zheng Li et al.
2026-09 · DOI: 10.1111/jns.70166Neuropathy in Val122Ile Hereditary Transthyretin ( ATTR ) Amyloidosis: A Multicenter Retrospective Cohort Study
Anna Paula Paranhos, Marcela Câmara Machado Costa, Carolina Lavigne Moreira, Diogo Fernandes dos Santos et al.
2026-09 · DOI: 10.1111/jns.70160Reviews
Community Reviews
Version History
October 2, 2026 at 8:28 pm
October 2, 2026